Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer

Free Subscription 22.12.2025 1 Abdom Radiol (NY) 1 ACS Appl Mater Interfaces 1 Adv Sci (Weinh) 1 AJR Am J Roentgenol 2 Am J Surg Pathol 1 Asian Nurs Res (Korean Soc Nurs Sci) 1 Biomater Res 1 Biomed Pharmacother 1 BMC Urol 1 Can Urol Assoc J 1 Cancer Treat Res Commun 1 Cell Death Dis 3 Cureus 1 Drug Resist Updat 1 Endocr Pract 1 Eur Urol 2 Eur Urol Focus 3 Eur Urol Oncol 1 Expert Rev Anticancer Ther 2 Front Immunol 1 Front Nutr 1 Front Oncol 1 Heliyon 1 Int J Med Sci 3 Int J Surg 1 iScience 1 J Clin Oncol 1 J Exp Clin Cancer Res 1 J Mol Med (Berl) 1 J Transl Med 1 Minerva Urol Nephrol 1 Mol Med Rep 1 N Engl J Med 1 Nat Rev Clin Oncol 1 Oncol Ther 1 Pathol Res Pract 1 Radiol Phys Technol 1 Scand J Urol 1 Semin Oncol Nurs 1 Tob Induc Dis 1 Transl Oncol 1 Urol Oncol 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. WANG L, Wang Z, Liu Z, Zhou Y, et al
   CT-derived tumor extracellular volume fraction for predicting recurrence in non-muscle-invasive bladder cancer.
   Abdom Radiol (NY). 2025 Dec 19. doi: 10.1007/s00261-025-05327.
   PubMed         Abstract available
   
   

   
   ACS Appl Mater Interfaces

2. WU R, Liao R, Yin H, He W, et al
   Urease-Powered Nanomotors for Enhanced Mucosal and Tumor Penetration To Augment Sonodynamic Therapy in Bladder Cancer.
   ACS Appl Mater Interfaces. 2025 Dec 15. doi: 10.1021/acsami.5c17665.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

3. 
   Correction to "ETV4 Mediated Tumor-Associated Neutrophil Infiltration Facilitates Lymphangiogenesis and Lymphatic Metastasis of Bladder Cancer".
   Adv Sci (Weinh). 2025 Dec 16:e73278. doi: 10.1002/advs.73278.
   PubMed        
   
   

   
   AJR Am J Roentgenol

4. CHAI JL
   Vesical Imaging-Reporting and Data System: The Answer to Staging of Bladder Cancer?
   AJR Am J Roentgenol. 2025 Dec 17. doi: 10.2214/AJR.25.34390.
   PubMed        
   
   

   
   Am J Surg Pathol

5. ZHAO M, Yang X, Zhang Z, Fang R, et al
   Molecular Heterogeneity and Clinicopathologic Correlations in Inflammatory Myofibroblastic Tumors of the Urinary Bladder: A Study of 20 Cases With Predominant FN1::ALK Fusions and Novel Kinase Rearrangements.
   Am J Surg Pathol. 2026;50:118-131.
   PubMed         Abstract available
   
   
6. LI H, Parimi V, Johnson B 3rd, Kamanda S, et al
   Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease.
   Am J Surg Pathol. 2026;50:51-61.
   PubMed         Abstract available
   
   

   
   Asian Nurs Res (Korean Soc Nurs Sci)

7. CHEN YR, Jou YC, Lin YC, Huang HP, et al
   Influencing Factors of Unmet Care Needs Among Taiwanese Non-Muscle Invasive Bladder Cancer during Acute Stage of Survivorship: A Preliminary Study.
   Asian Nurs Res (Korean Soc Nurs Sci). 2025 Dec 13:S1976-1317(25)00139.
   PubMed         Abstract available
   
   

   
   Biomater Res

8. YU C, Zhang Y, Wang N, Wei W, et al
   Erratum to "Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA".
   Biomater Res. 2025;29:0268.
   PubMed         Abstract available
   
   

   
   Biomed Pharmacother

9. LI JR, Yu TM, Ou YC, Wu CC, et al
   Indoxyl sulfate promoted glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2.
   Biomed Pharmacother. 2025;193:118865.
   PubMed         Abstract available
   
   

   
   BMC Urol

10. ZHOU J, Zhang C, Wang X, Xing J, et al
    Vitamin D promotes apoptosis and enhances cisplatin sensitivity in bladder cancer cells by inhibiting the Warburg effect through the AKT/mTOR pathway.
    BMC Urol. 2025 Dec 15. doi: 10.1186/s12894-025-01994.
    PubMed        
    
    

    
    Can Urol Assoc J

11. PEREZ-LONDONO A, Kaul S, Fleishman A, Korets R, et al
    Contemporary outcomes and disease burden of high-grade T1 bladder cancer.
    Can Urol Assoc J. 2025 Nov 25. doi: 10.5489/cuaj.9329.
    PubMed         Abstract available
    
    

    
    Cancer Treat Res Commun

12. SAFIRI S, Hassanzadeh K, Shamekh A, Tahmasbi F, et al
    The burden of bladder cancer in the MENA region: a 3-decade analysis.
    Cancer Treat Res Commun. 2025;46:101066.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

13. SUN Y, Wang J, Gu D, Lou H, et al
    Targeting the SMAD3/CISD2 axis suppresses bladder cancer progression by promoting ferroptosis in mesenchymal-like bladder cancer cells.
    Cell Death Dis. 2025 Dec 18. doi: 10.1038/s41419-025-08339.
    PubMed         Abstract available
    
    

    
    Cureus

14. MASOOD S, Shaikh A, Brar Y
    Evaluating Molecular and Immune Biomarkers in Predicting Bladder Cancer Recurrence and Survival: A Systematic Review.
    Cureus. 2025;17:e96824.
    PubMed         Abstract available
    
    
15. ISHTIAQ S, Farouk K
    Artificial Intelligence as a Tool in the Diagnosis of Bladder Cancer: A Narrative Review.
    Cureus. 2025;17:e96958.
    PubMed         Abstract available
    
    
16. NAKAYAMA M, Yanagihara T, Fujimoto M, Kushima N, et al
    A Rare Case of Hemophagocytic Lymphohistiocytosis Triggered by Intravesical Bacillus Calmette-Guerin (BCG) for Bladder Cancer.
    Cureus. 2025;17:e96711.
    PubMed         Abstract available
    
    

    
    Drug Resist Updat

17. XU G, Zheng M, Wu Z, Xie T, et al
    Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis.
    Drug Resist Updat. 2025;85:101343.
    PubMed         Abstract available
    
    

    
    Endocr Pract

18. RAO Y, Meng S, Yi-Wen Yu E, Chen Y, et al
    Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Endocr Pract. 2025 Dec 17:S1530-891X(25)01328.
    PubMed         Abstract available
    
    

    
    Eur Urol

19. PANDOLFO SD, Bukavina L, Autorino R
    Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Dec 17:S0302-2838(25)04860-2. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    

    
    Eur Urol Focus

20. MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
    Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2025 Dec 18:S2405-4569(25)00364.
    PubMed         Abstract available
    
    
21. COCA MEMBRIBES S, Powles T
    Does Adjuvant Immune Checkpoint Inhibition Therapy Have a Future in Operable Bladder Cancer?
    Eur Urol Focus. 2025 Dec 15:S2405-4569(25)00370.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

22. D'ANDREA D, Shariat SF
    Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guerin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-
    Eur Urol Oncol. 2025 Dec 15:S2588-9311(25)00329.
    PubMed        
    
    
23. GROBET-JEANDIN E, Diamant E, Gabriel PE, De Olivera A, et al
    Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort.
    Eur Urol Oncol. 2025 Dec 18:S2588-9311(25)00294.
    PubMed         Abstract available
    
    
24. SHAH CP, Gray J, Lord-McKenzie T, Mariappan P, et al
    Clinical Evaluation of a Novel Deintensified Surveillance Protocol for Low-risk Non-muscle-invasive Bladder Cancer: A Prospective Study in 250 Patients.
    Eur Urol Oncol. 2025 Dec 17:S2588-9311(25)00292.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

25. SARAN MANIVASAGAM S, Raman JD, Aminsharifi A
    Integrating artificial intelligence across the bladder cancer continuum: progress, promise, and pitfalls.
    Expert Rev Anticancer Ther. 2025 Dec 14. doi: 10.1080/14737140.2025.2604617.
    PubMed         Abstract available
    
    

    
    Front Immunol

26. CHANG Z, Wang J, Cao J, Fan X, et al
    Targeting PSMB5-induced PANoptosis in bladder cancer: multi-omics insights and TCM candidate discovery.
    Front Immunol. 2025;16:1656682.
    PubMed         Abstract available
    
    
27. ZHANG F, Wang J, Yu Y, Zhang C, et al
    Neoadjuvant chemoradiotherapy plus programmed cell death protein-1 blockade versus chemoradiotherapy alone for muscle-invasive bladder cancer: a real-world comparative study.
    Front Immunol. 2025;16:1711690.
    PubMed         Abstract available
    
    

    
    Front Nutr

28. SUN L, Liu C
    The modifying effect of dietary index for gut microbiota on the association between urinary arsenic exposure and bladder cancer risk: a nationwide cohort study.
    Front Nutr. 2025;12:1723496.
    PubMed         Abstract available
    
    

    
    Front Oncol

29. ZHANG L, Yang G, Huang L, Deng A, et al
    The S100 protein family in bladder cancer: mechanisms, clinical value, and targeted therapeutic prospects.
    Front Oncol. 2025;15:1683039.
    PubMed         Abstract available
    
    

    
    Heliyon

30. WU N, Sun Y, Xue D, He X, et al
    Retraction notice to "FTO promotes the progression of bladder cancer via demethylating m(6)A modifications in PTPN6 mRNA" [Heliyon 10 (2024) e34031].
    Heliyon. 2025;11:e43978.
    PubMed         Abstract available
    
    

    
    Int J Med Sci

31. HWANG TI, Peng PW, Chi MS, Chou KY, et al
    Thrombospondin-4 drives lymphangiogenesis through cooperation with VEGF-C in human bladder cancer.
    Int J Med Sci. 2026;23:204-215.
    PubMed         Abstract available
    
    

    
    Int J Surg

32. YANG L, Li S, Zhou Q, Liu W, et al
    Integrated transcriptomic evidence reveals RGS20 as a link between immune modulation and prognosis in bladder cancer.
    Int J Surg. 2025 Dec 16. doi: 10.1097/JS9.0000000000004451.
    PubMed        
    
    
33. ZHANG Y, Lv S, Li Z, Wang X, et al
    Clinical trial landscape of cellular therapies in bladder cancer.
    Int J Surg. 2025 Dec 16. doi: 10.1097/JS9.0000000000004060.
    PubMed        
    
    
34. CHEN H
    Changing paradigms in female bladder cancer management: global epidemiology and future projections from 1990 to 2040.
    Int J Surg. 2025 Dec 16. doi: 10.1097/JS9.0000000000004462.
    PubMed         Abstract available
    
    

    
    iScience

35. WANG X, Liu B, Tang Y, Wang J, et al
    PSMD8 cooperates with USP14 to promote bladder cancer progression by inhibiting ferroptosis.
    iScience. 2025;28:113938.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

36. GORE JL, Wolff EM, Nash MG, Comstock BA, et al
    Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2025 Dec 15:JCO2501324. doi: 10.1200/JCO-25-01324.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

37. XU G, Liang S, Hu G, Zhao W, et al
    HDAC2 as a therapeutic target in bladder cancer: insights into the altered epigenetic regulation and lysine lactylation.
    J Exp Clin Cancer Res. 2025 Dec 17. doi: 10.1186/s13046-025-03610.
    PubMed         Abstract available
    
    

    
    J Mol Med (Berl)

38. JIANG N, Ma W, Jin X
    The promising arsenal of ferroptosis inducers in bladder cancer.
    J Mol Med (Berl). 2025;104:9.
    PubMed         Abstract available
    
    

    
    J Transl Med

39. WANG Z, Miao J, Wang M, Ying Y, et al
    Single-cell and spatial atlas unveil tumor-specific microenvironment convergence and a prognosis-associated PLXDC1+ myofibroblast population in metastatic bladder cancer.
    J Transl Med. 2025 Dec 15. doi: 10.1186/s12967-025-07534.
    PubMed        
    
    

    
    Minerva Urol Nephrol

40. TULONE G, Pavan N, Fasciana TM, Martorana A, et al
    Exploring the influence of the bladder microbiome on BCG immunotherapy outcomes for high-risk non muscle invasive bladder cancer.
    Minerva Urol Nephrol. 2025;77:820-827.
    PubMed         Abstract available
    
    

    
    Mol Med Rep

41. HUANG J, Wu Z, Wang G, Cai Y, et al
    [Retracted] N?Myc downstream?regulated gene 2 suppresses the proliferation of T24 human bladder cancer cells via induction of oncosis.
    Mol Med Rep. 2026;33:67.
    PubMed         Abstract available
    
    

    
    N Engl J Med

42. DYRSKJOT L
    ctDNA-Guided Therapy in Bladder Cancer - Ready?
    N Engl J Med. 2025;393:2470-2471.
    PubMed        
    
    

    
    Nat Rev Clin Oncol

43. SUELMANN BBM, van der Heijden MS
    From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.
    Nat Rev Clin Oncol. 2025 Dec 15. doi: 10.1038/s41571-025-01113.
    PubMed        
    
    

    
    Oncol Ther

44. BANGS R, Li R
    Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast).
    Oncol Ther. 2025 Dec 15. doi: 10.1007/s40487-025-00409.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

45. CUI H, Fan X
    Targeting the NR4A3-RNF139-ATF6 pathway as a therapeutic and diagnostic strategy in bladder cancer.
    Pathol Res Pract. 2025;278:156301.
    PubMed         Abstract available
    
    

    
    Radiol Phys Technol

46. CATONA GM, Marcu LG
    The role of cone beam CT in personalization of bladder cancer radiotherapy.
    Radiol Phys Technol. 2025 Dec 15. doi: 10.1007/s12194-025-00994.
    PubMed         Abstract available
    
    

    
    Scand J Urol

47. STARLANDER G, Shkair R, Wagenius M, Blackberg M, et al
    Association between symptoms of acute cystitis and findings of bladder cancer in the Swedish standardized pathway for macroscopic haematuria.
    Scand J Urol. 2025;60:238-243.
    PubMed         Abstract available
    
    

    
    Semin Oncol Nurs

48. ARTHUSO FZ, Fairey AS, Boule NG, Jacobsen NE, et al
    Exercise During or After Intravesical Therapy for Bladder Cancer: A Randomized Feasibility Trial.
    Semin Oncol Nurs. 2025 Dec 18:152090. doi: 10.1016/j.soncn.2025.152090.
    PubMed         Abstract available
    
    

    
    Tob Induc Dis

49. YANG B, Yuan J, Song W, Wang H, et al
    The role of smoking in bladder cancer risk: Unveiling racial and ethnic disparities in US and global populations, a secondary dataset analysis.
    Tob Induc Dis. 2025;23.
    PubMed         Abstract available
    
    

    
    Transl Oncol

50. PENG Q, Zhang M, Zhao S, Guo Y, et al
    Multi-omics characterization identifies AHCY as a prognostic biomarker driving immunometabolic reprogramming in bladder cancer.
    Transl Oncol. 2025;64:102652.
    PubMed         Abstract available
    
    

    
    Urol Oncol

51. ZEIN M, Sebai T, AlJardali B, Ghandour Y, et al
    The changing landscape of urinary diversion post cystectomy: A 15-year analysis of the NSQIP database.
    Urol Oncol. 2026;44:63.
    PubMed         Abstract available
    
    

    
    World J Urol

52. SHWEIKI D
    Sex disparities in bladder cancer diagnosis: evidence from the UK Biobank.
    World J Urol. 2025;44:39.
    PubMed         Abstract available
    
    
53. BERTRAND C, Ouzaid I, Guerrero-Ramos F, Marcq G, et al
    A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives.
    World J Urol. 2025;44:44.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.